International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company dedicated to the research, development and commercialization of human parthenogenetic stem cell (hpSC) technologies. Established in 2007 and headquartered in Carlsbad, California, the company harnesses parthenogenesis to generate pluripotent stem cell lines that possess a stable, homozygous human leukocyte antigen (HLA) profile. These hpSC lines serve as the basis for a wide range of therapeutic and research applications, offering a renewable source of cells for regenerative medicine, drug discovery, and personalized health care.
ISCO’s core offerings include proprietary stem cell-derived products and services. Through its subsidiary, Lifeline Cell Technology, the company produces primary human cells and standardized cell culture media, which are distributed to academic, industrial, and government research institutions. In parallel, ISCO advances preclinical programs targeting degenerative conditions such as Parkinson’s disease, age-related macular degeneration and Type I diabetes. By differentiating hpSC lines into specific cell types, the company aims to develop off-the-shelf therapeutic candidates that could address immune rejection concerns and increase the safety profile of cell-based treatments.
In addition to its therapeutic pipeline, ISCO has explored cosmetic and personal care applications of stem cell technology. Its Lifeline Stem Cell brand offers serums and topical formulations that incorporate stem cell-derived conditioned media, peptides and growth factors intended to promote skin rejuvenation. These consumer products are marketed in North America and select international markets, reflecting the company’s broader strategy to leverage its technology platform across multiple industries.
Leadership at ISCO is guided by founder and Chief Executive Officer Dr. Ruslan Semechkin, whose experience in stem cell science and business development has steered the company through key milestones, including its Nasdaq listing and strategic acquisitions. Supported by a board of directors with backgrounds in biopharmaceutical development, clinical research and regulatory affairs, the team focuses on advancing stem cell innovations from preclinical proof-of-concept through to commercialization. With operations spanning the United States, Europe and Asia, International Stem Cell Corporation continues to build on its foundational hpSC platform to address unmet needs in regenerative medicine, research tools and consumer health.
AI Generated. May Contain Errors.
